Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 22OTHER 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 9Head & Neck 8Genitourinary 4Breast 4Gastrointestinal 3Thoracic 2Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Prostatic Neoplasms 4399Urinary Bladder Neoplasms 1078Carcinoma, Renal Cell 1041Kidney Neoplasms 567Breast Neoplasms 453Neoplasms 403Carcinoma, Transitional Cell 297Neoplasm Metastasis 250Lung Neoplasms 242Testicular Neoplasms 202Melanoma 194Colorectal Neoplasms 193Ovarian Neoplasms 163Carcinoma, Non-Small-Cell Lung 150Non-Muscle Invasive Bladder Neoplasms 135Sarcoma 134Pancreatic Neoplasms 124Colonic Neoplasms 121Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Wilms Tumor 108Recurrence 106Motor Activity 100Stomach Neoplasms 89Urologic Neoplasms 88Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 79Adenocarcinoma 78

Interventions

toripalimab 1durvalumab 1Surveys and Questionnaires 1Nivolumab 1Mitomycin 1Gemcitabine 1Docetaxel 1Cystoscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Carcinoma in Situ × Genitourinary × Clear all
NCT07322263 2026-04-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

University of Iowa

Phase 2 Recruiting
174 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07189793 2025-09-24

OHAI-NMIBC-01

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
106 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
17 enrolled 9 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡